Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 4/20 | 0.66 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30601698 | 0.87 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4615740 | 0.87 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1344002 | 0.87 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18299784 | 0.80 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22636866 | 0.80 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL28063755 | 0.80 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1736238 | 0.80 | GPR35 (0.59) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1509524 | 0.80 | VCAM1 (0.56) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2085253 | 0.79 | VCAM1 (0.66) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8409766 | 0.79 | VCAM1 (0.66) | VCAM1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| EP-1953146-B1 | METHODS OF MAKING 6-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL) AMINO-]-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | UNIV NEBRASKA (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-1594862-B1 | METHODS OF MAKING 6-[ (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-] -7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | UNIV NEBRASKA (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1594862-B1 | METHODS OF MAKING 6-[ (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-] -7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | UNIV NEBRASKA (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1953146-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl) amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | The Board of Regents of the University of Nebraska (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7268255-B2 | Process for the preparation of N-substituted formamides | LONZA AG (CH) | 2007-09-11 | — | — | US | disclosed |
| US-20070037985-A1 | Hydrogenating a corresponding nitroarene or nitroheteroarene with formic acid and/or ammonium formate as hydrogen donor and formylating agent in the presence of at least one noble metal-based hydrogenation catalyst and a vanadium or molybdenum compound as co-catalyst | KAMPFEN ULRICH | 2007-02-15 | — | — | US | disclosed |
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-08-26 | — | — | US | disclosed |
| US-6423724-B1 | PREVENTION, THERAPY DISEASE | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| EP-0734261-B1 | 7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5916900-A | TREATMENT OF NASAL CONGESTION, ASTHMA, COUGH, CARDIOVASCULAR DISORDERS, OCULAR DISORDERS, GASTROINTESTINAL DISORDERS, MIGRAINES, SUSBSTANCE ABUSE | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| US-5716966-A | RESPIRATORY SYSTEM DISORDERS; VISION DEFECTS; GASTROINTESTINAL DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5576437-A | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0734261-A1 | 7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995020386-A1 | 7-(2-IMIDAZOLINYLAMINO)QUINOLINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |
| US-4126617-A | PROPHYLAXIS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-3959289-A | PROPHYLACTICS IN ALLERGIES | THE UPJOHN COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | VCAM1 2036/4885GRIN2D 83/4885GRIN3B 224/4885 |
| US-20070037985-A1 | Hydrogenating a corresponding nitroarene or nitroheteroarene with formic acid and/or ammonium formate as hydrogen donor and formylating agent in the presence of at least one noble metal-based hydrogenation catalyst and a vanadium or molybdenum compound as co-catalyst | FH, NIT2, NCF1 | VCAM1 2528/4885GRIN2D 786/4885GRIN3B 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.